MaxCyte Inc. (MXCT)
NASDAQ: MXCT
· Real-Time Price · USD
2.79
-0.05 (-1.76%)
At close: May 01, 2025, 3:59 PM
2.76
-1.25%
After-hours: May 01, 2025, 04:10 PM EDT
-1.76% (1D)
| Bid | 2.7 |
| Market Cap | 297.15M |
| Revenue (ttm) | 38.63M |
| Net Income (ttm) | -41.05M |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -7.17 |
| Forward PE | -9.47 |
| Analyst | Buy |
| Ask | 3.05 |
| Volume | 234,896 |
| Avg. Volume (20D) | 631,293 |
| Open | 2.79 |
| Previous Close | 2.84 |
| Day's Range | 2.75 - 2.88 |
| 52-Week Range | 2.21 - 5.26 |
| Beta | 1.21 |
About MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 30, 2021
Employees 114
Stock Exchange NASDAQ
Ticker Symbol MXCT
Website https://maxcyte.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MXCT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 222.00% from the latest price.
Stock ForecastsNext Earnings Release
MaxCyte Inc. is scheduled to release its earnings on May 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+11.59%
MaxCyte shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
+15.83%
MaxCyte shares are trading higher after the company raised its FY24 core revenue guidance and announced layoffs to save $5.8 million per year.
